The aim of this study was to assess the relationship between maternal viral load and mother-to-child transmission (MTCT) risk in hepatitis B envelope antigen (HBeAg)-positive mothers.
INTRODUCTION

H EPATITIS B VIRUS (HBV)
infection is a major global health problem. According to World Health Organization estimates, 257 million people are chronically infected with hepatitis B. 1 Hepatitis B virus infection not only causes acute or chronic hepatitis, but also leads to severe long-term, life-threatening complications, such as cirrhosis, liver failure, and hepatocellular carcinoma. More than 686 000 people die every year due to cirrhosis and liver cancer caused by HBV infection. 2 Hepatitis B virus infection acquired by mother-to-child transmission (MTCT) is typically considered to be one of the major causes of chronic infection. According to a previous study, newborns have a 90% chance of becoming chronic carriers after infection with HBV; in children <3 years old the chance is up to 50%. However, in adults the chance is only up to 5%. 3 After appropriate postnatal hepatitis B immunoglobulin and a series of HBV vaccines, the MTCT rate is significantly reduced, but is still 5-10%. 4 Therefore, effective prevention of MTCT of HBV from pregnant women to their newborns within the perinatal period is very important for interrupting chronic HBV infection.
Some studies have investigated the risk factors for MTCT in hepatitis B envelope antigen (HBeAg)-positive mothers.
Wong et al. found a linear association between duration of the first stage of labor and hepatitis B surface antigen (HBsAg) positivity in infants' cord blood. 5 Yang et al. reported elective cesarean section versus vaginal delivery could effectively reduce the rate of MTCT of HBV (elective cesarean section, 10.5%; vaginal delivery, 28.0%). 6 Yi et al. reported amniocentesis carried out on HBsAg+ mothers significantly increased the frequency of MTCT, especially in mothers with HBV-DNA >7 log10 copies/mL. 7 Some maternal and neonatal gene mutations or polymorphisms are related with MTCT, including Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms, 8 tumor necrosis factor-α 308G/A, and vitamin D receptor ApaI and TaqI genotypes, 9 HLA-DPA1 (rs3077) and HLA-DPB1 (rs9277535). 10 Most importantly, HBV viral factors directly impact MTCT. Yin et al. reported that HBV pre-S/S gene mutations is a risk factor of vaccination failure and frequently causes HBV MTCT. 11 Serum HBV-DNA level has been identified as the reliable marker of active HBV replication. Maternal HBV viral load is another important viral risk factor for MTCT. Many studies have shown increased risk of MTCT was related with higher maternal levels of HBV-DNA. Zhang et al. reported maternal-positive HBV-DNA was associated with higher MTCT incidence compared with negative, with odds ratio (OR) 11.362 (95% confidence interval [CI], 1.389-92.931). 12 Wen et al. found that predictive MTCT incidence at maternal viral load levels of 7, 8, and 9 log 10 copies/mL were 6.6% (95% CI, 0.5-12.6%; P = 0.033), 14.6% (95% CI, 5.6-23.6%; P = 0.001), and 27.7% (95% CI, 13.1-42.4%; P < 0.001), respectively. 13 Zou et al. reported that the incidence of immunoprophylaxis failure was 0%, 3.2% (3/95), 6.7% (19/282), and 7.6% (5/66) at mothers' pre-delivery HBV-DNA levels of <6, 6-6.99, 7-7.99, and ≥8 log 10 copies/mL, respectively (P < 0.001 for trend). 14 However, these studies included small sample sizes. As far as we know, there is no systematic review that summarizes HBV load and the risk of MTCT.
In this study, we aim to: (i) compare the MTCT risk between HBV-DNA-positive mothers and HBV-DNAnegative mothers; (ii) summarize the MTCT incidence in different HBV-DNA level stratifications; and (iii) find the dose-response relationship between HBV-DNA level and MTCT risk. The PROSPERO CRD registration ID of this study is 42 018 087 311. (TI = "mother-to-child transmission" OR TI = "intrauterine transmission" OR TI = "mother-to-infant transmission" OR TI = "utero transmission" OR TI = "vertical transmission"). We manually examined reference lists from retrieved articles and published reviews to identify additional manuscripts. The search was limited to English and Chinese articles.
METHODS
Search
Study eligibility
We defined studies as being eligible for inclusion in this analysis if they met the following criteria: (i) types of studies: observational studies (cohort studies and case-control studies) were included; (ii) types of participants: HBsAgpositive mother and their children with documented HBV serology at birth and at least once between 6 months and 3 years of age; (iii) types of exposure: compared maternal HBV-DNA positive with negative, or compared different HBV-DNA level stratifications for the outcome; and (iv) types of outcome: studies included MTCT incidence. Mother-to-child transmission was defined by HBsAg or HBV-DNA positivity in the child. A mother with multiple births was recognized as a mother-child pair. We excluded publications when: (i) mother-child pairs were coinfected with hepatitis A, C, D, or E virus or HIV; (ii) the number of MTCT was <3; and (iii) the study did not provide crude numbers in contingency tables or maternal HBV-DNA level stratifications.
Study selection and data extraction
Study selection was initially carried out by review of titles and abstracts. When there was any possibility that it might be relevant, the full text of the article was downloaded and then reviewed for data retrieval. The following data were abstracted onto standardized forms: first author, publication year, country, study design, year of enrollment, number of mother-child pairs, maternal age at delivery, HBV-DNA detection method, definition of HBV-DNA positive, antiviral therapy, vaccine, infant follow-up, MTCT incidence, crude numbers in contingency tables for HBV-DNA positive and MTCT risk, crude numbers of infant HBV infected and not infected in maternal HBV-DNA level stratifications, and the most fully adjusted ORs with 95% CIs for categories of HBV-DNA, or crude ORs. Data were extracted independently by two reviewers. Any differences of opinion were resolved by discussion and consensus reached by discussion with a third reviewer.
Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included observational studies. The NOS contains eight items, categorized into three dimensions including Selection (4), Comparability (1), and Exposure (3). A high-quality study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability. The NOS ranges from zero up to nine stars. 15 Two reviewers independently assessed the quality of studies. Disagreements were resolved by a third reviewer.
Statistical analyses
First, we compared the MTCT incidence between HBV-DNA-positive mothers and -negative mothers. The meta-analysis model was chosen by heterogeneity between included studies. Heterogeneity was explored by the χ 2 -test and inconsistency (I 2 ) statistics; P < 0.05 for the χ 2 -test or an I 2 value ≥25% represented heterogeneity. 16 In the absence of significant heterogeneity, studies were pooled using a fixed-effect model. If heterogeneity was observed, a random-effects model was used. Overall effects of OR were determined using the Z test. Publication bias was evaluated using funnel graphs, Egger's regression test, and Begg's adjusted rank correlation test. We undertook subgroup meta-analyses by country (China and non-China), definition of HBV-DNA positive (>3 log 10 copies/mL and not >3 log 10 copies/mL), and MTCT diagnosis time (24 h, 6-12 months, and >1 year). We also conducted meta-regression by MTCT incidence and publication year. Sensitivity analysis was carried out by only included prospective studies.
Second, we pooled the MTCT incidence in the maternal HBV-DNA level stratifications (<6 log 10 copies/mL, 6-8 log 10 copies/mL, and >8 log 10 copies/mL) assuming random effects and binomial rate. Two-sided 95% CIs for the incidences with the Freeman-Tukey double arcsine variance-stabilizing transformation are also provided. 17 The 95% CI excluding zero indicates a statistically significant overall result.
Finally, we examined the dose-response relationship of maternal HBV-DNA level and MTCT risk. The doseresponse meta-analysis was carried out using the method proposed by Greenland and Longnecker 18 and Orsini et al. 19, 20 We carried out linear dose-response analyses from the natural logarithm of the ORs across categories of HBV-DNA. This analysis is performed on the basis of the data for categories of HBV-DNA levels on median dose, number of cases and participants, and the adjusted OR with its 95% CI (or substituted by crude OR). We also assessed a potential non-linear dose-response relationship between HBV-DNA and MTCT risk using restricted cubic splines with three knots at 10%, 50%, and 90% of the distribution. A likelihood ratio test was used to assess the difference between the non-linear and linear models to test for non-linearity.
All statistical analyses were undertaken with Stata software, version 13.0 (Stata, College Station, TX, USA). Two-sided P < 0.050 was considered statistically significant. The following Stata commands were used: metan (HBV-DNA positive vs. negative, sensitivity analysis, and pooled MTCT incidence), metafunnel (funnel plot), metabias (Egger's test and Begg's test), metareg (metaregression analyses), and glst (dose-response analyses).
RESULTS
Characteristics of included studies
W E IDENTIFIED 346 unique papers after searching PubMed and Web of Science. Of these, 21 publications 7,12-14,21-37 with 10 142 mother-child pairs were eligible for the evaluation of the relationship of maternal viral load and HBV MTCT risk. Figure 1 shows the stages in identifying studies for inclusion in the review. Most of the studies were published in the last decade and were carried out in the China. All identified studies followed an observational design, with six prospective cohorts and five case-control studies. All of the studies detected HBV-DNA by polymerase chain reaction, most of studies defined HBV-DNA positive as HBV-DNA >3 log 10 copies/mL. The MTCT incidence ranged from 1.54% to 45.5%. The NOS for methodological quality assessment of the included studies scored at 7-8. A quality assessment scale showed the publications that met eligibility have acceptable quality to be included in our meta-analyses. Characteristics of the 21 articles included in the metaanalyses are shown in Table 1 .
Incidence of MTCT compared between maternal HBV-DNA-positive and -negative groups
Nineteen publications 7,12-14,21-23,25,26,28-37 with 9033 mother-child pairs met eligibility for this comparison. The mean MTCT incidence in the maternal HBV-DNApositive group was 13.1% (range, 3.1-81.5%), compared with 4.2% (0.0-39.4%) in the maternal HBV-DNAnegative group. The MTCT incidence between the two groups is listed in Table 1 .
There was significant heterogeneity between the included studies (χ 2 (18) = 106.61, P < 0.00001; I 2 = 81.3%). The summary MTCT OR of maternal HBV-DNA positive compared with maternal HBV-DNA negative was 9.895 (95% CI, 5.333-18.359; Z = 7.27, P < 0.00001) by random-effects model (Fig. 2) .
The funnel plot showed asymmetry, which indicated evidence of publication bias (Fig. 3) . Begg's test (z = À0.98, P = 0.327) and Egger's test (t=À3.23, P = 0.005) also suggested publication bias.
Subgroup meta-analysis by country showed the summary MTCT OR was 10.323 (95% CI, 5.315-20.052; Z = 6.89, P < 0.00001) in the China subgroup, and 7.387 (95% CI, 1.231-44.326; Z = 2.19, P = 0.029) in the non-China subgroup (Fig. 4a) . Subgroup meta-analysis by HBV-DNA positive definition showed the summary MTCT OR was 4.891 (95% CI, 2.836-8.433; Z = 5.70, P < 0.00001) in the >3 log 10 copies/mL subgroup; in the not >3 log 10 copies/mL subgroup, the summary MTCT OR was 25.186 (95% CI, 9.411-67.404; Z = 6.42, P < 0.00001) (Fig. 4b) . Subgroup meta-analysis by MTCT diagnosis time showed the summary MTCT OR was 4.292 (95% CI, 2.297-8.021; Z = 4.57, P < 0.00001) in the 24 h subgroup, 16.808 (95% CI, 6.708-42.118; Z = 6.02, P < 0.00001) in the 6-12 months subgroup, and 20.040 (95% CI, 0.673-597.149; Z = 1.73, P = 0.083) in the >1 year subgroup (Fig. 4c) .
Meta-regression analyses showed that MTCT incidence (t = À0.62, P = 0.543) and year of publication (t = À0.20, P = 0.847) were not related with MTCT risk (Fig. 5) .
A sensitivity analysis including only prospective studies showed the summary MTCT OR was 6.990 (95% CI, 4.666-10.472; Z = 9.43, P < 0.00001) (Fig. 6 ).
Incidence of MTCT in different maternal HBV-DNA level stratifications
Ten publications [12] [13] [14] 21, 23, 24, 26, 28, 31, 37 with 3258 motherchild pairs met eligibility for the MTCT incidence for <6 log 10 copies/mL of maternal HBV viral load. The MTCT incidence ranged from 0.0% to 6.7%. The pooled MTCT incidence was 2.754% (95% CI, 1.198-4.310%; Z = 3.47, P = 0.001) by random-effects model (Fig. 7a) .
Seven publications [12] [13] [14] 21, 24, 31, 37 with 1019 motherchild pairs met eligibility for the MTCT incidence for 6-8 log 10 copies/mL of maternal HBV viral load. The MTCT incidence ranged from 5.3% to 19.6%. The pooled MTCT incidence was 9.932% (95% CI, 6.349-13.516%; Z = 5.43, P < 0.00001) by random-effects model (Fig. 7b) .
Seven publications [12] [13] [14] 21, 24, 31, 37 with 232 motherchild pairs met eligibility for the MTCT incidence for >8 log 10 copies/mL of maternal HBV viral load. The MTCT incidence ranged from 7.6% to 33.3%. The pooled MTCT incidence was 14.445% (95% CI, 8.317-20.572%; Z = 4.62, P < 0.00001) by random-effects model (Fig. 7c) .
The MTCT incidence in different maternal HBV-DNA level stratifications are listed in Table 2 .
Dose-response relationship between HBV-DNA and MTCT risk
Fourteen publications [12] [13] [14] [21] [22] [23] [24] [26] [27] [28] [29] 31, 32, 37 with 8851 mother-child pairs met eligibility for the evaluation of the dose-response relationship of maternal viral load and HBV MTCT risk. Linear dose-response showed significant and evolutionary risk of HBV MTCT risk along with maternal viral load increasing, with OR 1.393 (95% CI, 1.218-1.594) for each log 10 copy/mL increase. Several representative points value enhanced the association: the point estimate of maternal viral load at 6 log 10 copies/mL had an increased OR of MTCT 2.705 (95% CI, 1.808-4.047) compared with reference (3 log 10 copies/mL), whereas maternal viral load at 9 log 10 copies/mL had an increased OR of MTCT 7.316 (95% CI, 3.268-16.378) compared with the reference. A significant non-linear dose-response association was also found between maternal viral load and HBV MTCT risk (model χ 2 = 23.43, P < 0.00001). Linear dose-response and nonlinear dose-response are listed in Figure 8 .
DISCUSSION
I N OUR META-ANALYSIS, we found the mean MTCT incidence was higher in the maternal HBV-DNA-positive group compared with the -negative group (13.1% vs.
4.2%)
, with the pooled OR 9.895 (95% CI, 5.333-18.359; Z = 7.27, P < 0.00001). A sensitivity analysis that included only prospective studies showed the results were robust. In the linear dose-response model, the MTCT risk increased along with maternal viral load, with OR 1.393 (95% CI, 1.218-1.594) for each log 10 copy/mL increase. Yin et al. reported the adjusted OR of MTCT increased by 1.57 (95% CI, 1.12-2.21) for each log 10 IU/mL increase, adjusted by pregnancy-induced hypertension syndrome, HBeAg, HBeAb, and other risk factors by the logistic model. 37 Liu et al. reported the adjusted OR 2.44 (95% CI, 1.13-5.29; P = 0.023) for each log 10 IU/mL increase, adjusted by the delivery mode, also by logistic regression. 24 These two adjusted ORs were similar to our pooled ORs from the linear dose-response model. The placenta represents an efficient barrier for HBeAg transfer and that the HBeAg does not tolerize cytotoxic T cells. 38 However, when the HBV load is increased, HBsAg is expressed in cells of the ovarian follicle or placental capillary endothelium, 39 and HBsAg can pass through the placenta by cellular transfer, possibly contributing to MTCT. 39, 40 Our non-linear dose-response model showed that the MTCT risk increased rapidly when HBV-DNA was <7 log 10 copy/mL, but MTCT was maintained at a higher risk when HBV-DNA was ≥7 log10 copy/mL (Fig. 8) .
Lowering the level of maternal HBV-DNA during pregnancy is essential for the prevention of MTCT in mothers with high viremia. 3 The European Association for the Study of the Liver and the Asian Pacific Association for the Study of the Liver suggest that, in addition to neonatal immunoprophylaxis, treatment with antiviral agents such as tenofovir or telbivudine during pregnancy, beginning at 28-32 weeks of gestation, may be safe and effective in preventing MTCT. 3 However, there is still no consensus on the optimal cut-off value of maternal viral load for antiviral treatment. Some randomized controlled trials use different cut-off values for antiviral treatment, which included 6 log 10 copies/mL, 41 7 log 10 copies/mL, 42 and 1000 MEq/mL (approximately 9 log 10 copies/mL). 43 However, most studies regarded viral load of HBV-DNA >6 log 10 copies/mL (approximately 5.3 log 10 IU/mL) as the main risk of MTCT. 44, 45 Yi et al. recommended HBV-DNA >6 log 10 copies/mL as the cut-off for antiviral therapy in pregnant women. 3 In our included studies, some 13, 14, 21, 24 reported no MTCT in the <6 log 10 copies/mL stratified level. However, our metaanalysis showed in the maternal HBV-DNA <6 log 10 copies/mL stratified level that the pooled MTCT incidence was 2.754% (95% CI, 1.198-4.310%). The result indicated that newborns are still at risk when HBV-DNA <6 log 10 copies/mL. Therefore, we think that antiviral treatment should be given when mothers are HBV-DNApositive, rather than at >6 log 10 copies/mL. However, this inference should be confirmed by other randomized controlled trials. Wakano et al. also reported that, if a first child became an HBV carrier despite immunoprophylaxis, antiviral therapy is recommended in the second pregnancy. 46 Our meta-analysis also found the pooled MTCT incidence was 9.932% (95% CI, 6.349-13.516%) in the 6-8 log 10 copies/mL stratified level, and 14.445% (95% CI, 8.317-20.572%) in the >8 log 10 copies/mL stratified level. The results also showed the MTCT incidence increased along with maternal HBV viral load.
There are some limitations in this meta-analysis. First, some of the included studies were retrospective casecontrol studies. The most important drawback in casecontrol studies relates to the difficulty of obtaining reliable information about individuals' exposure status over time. Case-control studies are therefore placed low in the hierarchy of evidence. Second, only a few studies reported adjusted ORs of stratified HBV-DNA levels. We used crude ORs for the dose-response meta-analysis, which was calculated from raw data provided by included studies. Some other risk factors will affect the MTCT, such as prolonged labor, 5 vaginal delivery, 6 amniocentesis, 7 maternal gene mutations or polymorphisms, [8] [9] [10] [11] or others. Crude ORs could lead to bias. Third, significant heterogeneity was found between studies. We carried out subgroup analyses by country, HBV-DNA positive definition, and MTCT diagnosis time. We also evaluated meta-regression analysis by the MTCT incidence and the year of publication. However, we still did not find the potential source of heterogeneity. Finally, there was publication bias in the meta-analysis. These limitations need to be considered when evaluating the conclusion. 
